TERBINAFINE Drug Patent Profile
✉ Email this page to a colleague
When do Terbinafine patents expire, and when can generic versions of Terbinafine launch?
Terbinafine is a drug marketed by Sun Pharma Canada, Aurobindo Pharma, Breckenridge Pharm, Chartwell, Cipla, Emed Medcl, Gedeon Richter Usa, Glenmark Pharms Ltd, Heritage Pharma Avet, Invagen Pharms, Mylan, Natco Pharma, Orbion Pharms, Roxane, Senores Pharms, and Wockhardt. and is included in sixteen NDAs.
The generic ingredient in TERBINAFINE is terbinafine hydrochloride. There are twenty-seven drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the terbinafine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Terbinafine
A generic version of TERBINAFINE was approved as terbinafine hydrochloride by SUN PHARMA CANADA on July 2nd, 2007.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TERBINAFINE?
- What are the global sales for TERBINAFINE?
- What is Average Wholesale Price for TERBINAFINE?
Summary for TERBINAFINE
| US Patents: | 0 |
| Applicants: | 16 |
| NDAs: | 16 |
| Drug Prices: | Drug price information for TERBINAFINE |
| Drug Sales Revenues: | Drug sales revenues for TERBINAFINE |
| DailyMed Link: | TERBINAFINE at DailyMed |
Recent Clinical Trials for TERBINAFINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Swiss Cancer Institute | PHASE2 |
| Cairo University | NA |
| Assiut University | NA |



